Company intelligence / Profile preview
Shift Pharmaceuticals
Overland Park, Kansas, United Statesshiftpharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shift Pharmaceuticals develops antisense oligonucleotide therapeutics targeting the root causes of genetic neuromuscular diseases. Its lead program for spinal muscular atrophy has advanced through preclinical development with significant NIH grant support; IND-enabling studies are ongoing as of late 2023. No clinical trial results have been published yet
- Therapeutic areas
- Neurology
- Modalities
- Antisense oligonucleotide
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Missouri (technology licensing/collaboration)National Institutes of Health/NINDS/Blueprint for Neuroscience Research grant partnershipCharcot-Marie-Tooth Association collaboration on CMT1A therapy development
Beyond the preview
Go deeper on Shift Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shift Pharmaceuticals.